Death associated with rifampin and pyrazinamide 2-month treatment of latent mycobacterium tuberculosis.
We present the case of an elderly patient who died of fulminant hepatic failure in the course of receiving 2 months of treatment with pyrazinamide and rifampin for his latent tuberculosis. This 2-month course of treatment for latent tuberculosis is one of four options recently recommended by the Centers for Disease Control and Prevention. We discuss the safety of using this two-drug regimen to treat latent tuberculosis in stable elderly patients.
Medinger
Ann
A
Department of Veterans Affairs Medical Center, Washington, DC, USA. medingerbeeny@erols.com
D000368:Aged; D000904:Antibiotics, Antitubercular / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D017093:Liver Failure / Q000139:chemically induced*; D008297:Male; D011718:Pyrazinamide / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D011718:Pyrazinamide; D012293:Rifampin